与缺氧和免疫相关的TFRC是膀癌的预后因素和潜在的治疗标
Runhua Tang1,2, Haoran Wang1,2, Jianyong Liu1,2
1Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
European journal of medical research
|February 9, 2024
概括
这项研究开发了一个新的预测模型,使用缺氧和免疫基因来评估膀癌的预后和免疫治疗反应. 该模型识别了可能从特定治疗中受益的高风险患者,并突出了TFRC作为潜在的治疗目标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 膀癌,特别是肌肉侵入性膀癌 (MIBC),生存率和复发率低于最佳.
- 缺氧显著影响膀癌细胞的增殖,入侵和免疫反应.
- 了解缺氧和与免疫相关的基因对于膀癌的预后至关重要,但缺乏综合预后模型.
研究的目的:
- 研究膀癌 (BLCA) 中缺氧和免疫相关基因的预后价值.
- 开发一种新的预测模型,用于BLCA患者的整体存活率 (OS) 和免疫治疗反应.
主要方法:
- 分析了来自TCGA和GEO数据库的转录和临床数据.
- 通过LASSO分析构建和验证了氧和免疫特征的组合.
- 使用卡普兰-梅尔曲线和考克斯回归来评估预后准确性;使用TIDE分析评估免疫微环境和免疫治疗反应.
主要成果:
- 建立了8基因缺氧和免疫特征,识别了具有明显较差生存状况的高风险患者.
- 签名作为一个独立的预后因素,具有不同的检查点基因表达 (例如,PD-L1,CTLA4) 风险组之间.
- 高风险患者的免疫疗法反应较差,免疫逃逸增加;发现TFRC抑制了膀癌细胞的增殖和入侵.
结论:
- 低氧和免疫相关基因签名的结合为BLCA整体存活率和免疫治疗提供了一个新的预测模型.
- 这种签名可以帮助早期预后评估和膀癌患者的治疗选择.
- 对于未来的膀癌治疗来说,TFRC是一个潜在的治疗点.
相关概念视频
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...